Ceo
CurrentVigilant Diagnostics' (VigilantDx) disruptive platform technology makes disease detection easier, more cost-effective, and more accurate. The company's technology leverages the low cost, application breadth, and ubiquity of lateral flow assays (LFAs) enabling scalability of the platform broadly across disease vectors while retaining the benefits of LFA affordability and scalability.VigilantDx enhances existing commercial LFA sensitivity from 8-20 times, and up to 250 times with VigilantDx's enhanced LFA technology, rivaling ELISA and PCR level sensitivity. The technology provides quantifiable results and rapid turn-around time in a portable unit.VigilantDx's technology has been vetted through 9 peer-reviewed journal articles and is protected by a framework of issued and pending patents.